FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in the
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
(2)
Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatment
Nearly half of people were treated with faricimab every 16 weeks during the first year - the first time this level of durability has been achieved in a phase III study of an injectable eye medicine for neovascular age-related macular degeneration
Faricimab is the first investigational bispecific antibody designed for the eye and targets two distinct pathways - via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) - that drive a number of retinal conditions
F. Hoffmann-La Roche Ltd: Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
19.2
6.9
18.1
Tecentriq + Avastin (n=133)
24.0
(0.35-0.80)
Median follow-up: 15.6 months.
CR, complete response; DOR, duration of response; HR, hazard ratio; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression free response; PR, partial response; SD, stable disease.
See below for OS data from the primary analysis.
About the IMbrave150 study
IMbrave150 is a global Phase III, multicentre, open-label study of 501 people with unresectable HCC who had not received prior systemic therapy. People were randomised 2:1 to receive the combination of Tecentriq and Avastin or sorafenib. Tecentriq was administered intravenously (IV), 1200 mg on day 1 of each 21-day cycle, and Avastin was administered IV, 15 mg/kg on day 1 of each 21-day cycle. Sorafenib wa
F. Hoffmann-La Roche Ltd
Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years
Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years
The European Commission (EC) has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above
The EC has also approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above
Xofluza, with its rapid reduction in viral replication, could help patients recover more quickly, while also reducing the societal burden of influenza